Abstract
Objective To evaluate the efficacy of allogeneic hematopoietic stem-cell transplantation (allo-HSCT) in patients with myeloid sarcoma (MS). Methods The therapeutic effect of allo-HSCT on 16 patients with MS in our center was retrospectively analyzed. Among them, 5 patients were diagnosed as isolated MS, 10 patients were MS presenting with acute myeloid leukemia(AML)and 1 was accompanied with myelodysplastic syndrome/myeloproliferative neoplasm(MDS/MPN). Results All of the 16 patients were diagnosed as MS by pathological biopsies. Patients were initially treated with chemotherapy and then allo-HSCT. Hematopoiesis reconstitution was achieved in all the patients, with a median follow-up time of 36(4-106)months after transplantation, 7 patients died. The 3-year overall survival(OS) was 54.17%. Six patients(37.5%)relapsed after allo-HSCT, and the relapse was the major cause of death. Conclusions Allo-HSCT is an effective therapeutic option for patients with MS. Key words: Allogeneic hematopoietic stem cell transplantation; Myeloid sarcoma; Outcome
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
